Unicycive Research Development from 2010 to 2026
| UNCY Stock | USD 6.78 0.21 3.00% |
Research Development | First Reported 2019-03-31 | Previous Quarter 1.8 M | Current Value 3 M | Quarterly Volatility 1.9 M |
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 433.7 K, Interest Expense of 60.7 K or Selling General Administrative of 14.6 M, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0165 or PTB Ratio of 6.76. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
Unicycive | Research Development | Build AI portfolio with Unicycive Stock |
The evolution of Research Development for Unicycive Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Unicycive Therapeutics compares to historical norms and industry peers.
Latest Unicycive Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of Unicycive Therapeutics over the last few years. It is Unicycive Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Unicycive Research Development Regression Statistics
| Arithmetic Mean | 6,089,471 | |
| Geometric Mean | 1,455,595 | |
| Coefficient Of Variation | 144.85 | |
| Mean Deviation | 7,304,429 | |
| Median | 344,000 | |
| Standard Deviation | 8,820,295 | |
| Sample Variance | 77.8T | |
| Range | 23.8M | |
| R-Value | 0.84 | |
| Mean Square Error | 24.7T | |
| R-Squared | 0.70 | |
| Significance | 0.000026 | |
| Slope | 1,464,380 | |
| Total Sum of Squares | 1244.8T |
Unicycive Research Development History
About Unicycive Therapeutics Financial Statements
Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 23 M | 24.2 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.